138 related articles for article (PubMed ID: 22113985)
1. Esophageal and gastric cancer incidence and mortality in alendronate users.
Abrahamsen B; Pazianas M; Eiken P; Russell RG; Eastell R
J Bone Miner Res; 2012 Mar; 27(3):679-86. PubMed ID: 22113985
[TBL] [Abstract][Full Text] [Related]
2. Total cancer incidence and overall mortality are not increased among patients with Barrett's esophagus.
Schouten LJ; Steevens J; Huysentruyt CJ; Coffeng CE; Keulemans YC; van Leeuwen FE; Driessen AL; van den Brandt PA
Clin Gastroenterol Hepatol; 2011 Sep; 9(9):754-61. PubMed ID: 21570484
[TBL] [Abstract][Full Text] [Related]
3. Determinants of persistence with bisphosphonates: a study in women with postmenopausal osteoporosis.
Penning-van Beest FJ; Goettsch WG; Erkens JA; Herings RM
Clin Ther; 2006 Feb; 28(2):236-42. PubMed ID: 16678644
[TBL] [Abstract][Full Text] [Related]
4. Proton pump inhibitor use and the antifracture efficacy of alendronate.
Abrahamsen B; Eiken P; Eastell R
Arch Intern Med; 2011 Jun; 171(11):998-1004. PubMed ID: 21321287
[TBL] [Abstract][Full Text] [Related]
5. 14 day endoscopy study comparing risedronate and alendronate in postmenopausal women stratified by Helicobacter pylori status.
Thomson AB; Marshall JK; Hunt RH; Provenza JM; Lanza FL; Royer MG; Li Z; Blank MA;
J Rheumatol; 2002 Sep; 29(9):1965-74. PubMed ID: 12233894
[TBL] [Abstract][Full Text] [Related]
6. Atrial fibrillation in fracture patients treated with oral bisphosphonates.
Abrahamsen B; Eiken P; Brixen K
J Intern Med; 2009 May; 265(5):581-92. PubMed ID: 19141097
[TBL] [Abstract][Full Text] [Related]
7. The risk of missed gastroesophageal cancer diagnoses in users and nonusers of antisecretory medication.
Lassen A; Hallas J; de Muckadell OB
Gastroenterology; 2005 Oct; 129(4):1179-86. PubMed ID: 16230072
[TBL] [Abstract][Full Text] [Related]
8. Use of bisphosphonates and risk of breast cancer.
Vestergaard P; Fischer L; Mele M; Mosekilde L; Christiansen P
Calcif Tissue Int; 2011 Apr; 88(4):255-62. PubMed ID: 21253712
[TBL] [Abstract][Full Text] [Related]
9. Acute myocardial infarction and atherosclerosis of the coronary arteries in patients treated with drugs against osteoporosis: calcium in the vessels and not the bones?
Vestergaard P
Calcif Tissue Int; 2012 Jan; 90(1):22-9. PubMed ID: 22120197
[TBL] [Abstract][Full Text] [Related]
10. Heart failure in patients treated with bisphosphonates.
Grove EL; Abrahamsen B; Vestergaard P
J Intern Med; 2013 Oct; 274(4):342-50. PubMed ID: 23679231
[TBL] [Abstract][Full Text] [Related]
11. Risk of esophageal and gastric adenocarcinomas in relation to use of calcium channel blockers, asthma drugs, and other medications that promote gastroesophageal reflux.
Vaughan TL; Farrow DC; Hansten PD; Chow WH; Gammon MD; Risch HA; Stanford JL; Schoenberg JB; Mayne ST; Rotterdam H; Dubrow R; Ahsan H; West AB; Blot WJ; Fraumeni JF
Cancer Epidemiol Biomarkers Prev; 1998 Sep; 7(9):749-56. PubMed ID: 9752982
[TBL] [Abstract][Full Text] [Related]
12. Risk of newly diagnosed type 2 diabetes is reduced in users of alendronate.
Vestergaard P
Calcif Tissue Int; 2011 Oct; 89(4):265-70. PubMed ID: 21710315
[TBL] [Abstract][Full Text] [Related]
13. Oral alendronate use and risk of cancer in postmenopausal women with osteoporosis: A nationwide study.
Chiang CH; Huang CC; Chan WL; Huang PH; Chen TJ; Chung CM; Lin SJ; Chen JW; Leu HB
J Bone Miner Res; 2012 Sep; 27(9):1951-8. PubMed ID: 22532232
[TBL] [Abstract][Full Text] [Related]
14. Risk of atrial fibrillation associated with use of bisphosphonates and other drugs against osteoporosis: a cohort study.
Vestergaard P; Schwartz K; Pinholt EM; Rejnmark L; Mosekilde L
Calcif Tissue Int; 2010 May; 86(5):335-42. PubMed ID: 20309678
[TBL] [Abstract][Full Text] [Related]
15. Occurrence of gastrointestinal cancer in users of bisphosphonates and other antiresorptive drugs against osteoporosis.
Vestergaard P
Calcif Tissue Int; 2011 Dec; 89(6):434-41. PubMed ID: 22002678
[TBL] [Abstract][Full Text] [Related]
16. Nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric cancer.
Lindblad M; Lagergren J; García Rodríguez LA
Cancer Epidemiol Biomarkers Prev; 2005 Feb; 14(2):444-50. PubMed ID: 15734971
[TBL] [Abstract][Full Text] [Related]
17. Gastric and esophagus events before and during treatment of osteoporosis.
Vestergaard P; Schwartz K; Pinholt EM; Rejnmark L; Mosekilde L
Calcif Tissue Int; 2010 Feb; 86(2):110-5. PubMed ID: 19957165
[TBL] [Abstract][Full Text] [Related]
18. Alendronate and raloxifene use related to cardiovascular diseases: differentiation by different dosing regimens of alendronate.
Lu PY; Hsieh CF; Tsai YW; Huang WF
Clin Ther; 2011 Sep; 33(9):1173-9. PubMed ID: 21849210
[TBL] [Abstract][Full Text] [Related]
19. Upper gastrointestinal tolerability of alendronate sodium monohydrate 10 mg once daily in postmenopausal women: a 12-week, randomized, double-blind, placebo-controlled, exploratory study.
Adachi JD; Faraawi RY; O'Mahony MF; Nayar A; Massaad R; Evans JK; Yacik C
Clin Ther; 2009 Aug; 31(8):1747-53. PubMed ID: 19808133
[TBL] [Abstract][Full Text] [Related]
20. Reduced colon cancer incidence and mortality in postmenopausal women treated with an oral bisphosphonate--Danish National Register Based Cohort Study.
Pazianas M; Abrahamsen B; Eiken PA; Eastell R; Russell RG
Osteoporos Int; 2012 Nov; 23(11):2693-701. PubMed ID: 22392160
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
